Ozempic maker Novo Nordisk (NVO) announced mixed results today for a phase 2 trial of an experimental weight loss pill that ...

Novo Nordisk's shares fell nearly 5% on Friday after results from a Phase 2a trial of the Danish drugmaker's experimental ...

The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.

In early-stage trials, oral weight-loss drugs from Eli Lilly and Novo Nordisk have shown that they can help patients achieve ...

Novo Nordisk A/S's shares have stalled recently, but this looks like a natural digestion of gains from prior years. Click for ...

Novo Nordisk announced Phase 2a trial results for monlunabant. The trial demonstrated a weight reduction of 7.1 kg with a 10 ...

Novo Nordisk has multiple, strong upcoming, positive catalysts, related to its GLP-1 weight-loss drugs, Ozempic and Wegovy.

A drug approved to treat obesity in adults and teens is safe and effective for use in kids as young as 6 when combined with ...

Novo Nordisk said on Wednesday its highly anticipated experimental weight-loss pill amycretin was safe and tolerable for ...

In a late-stage clinical trial, a drug similar to Ozempic was shown to reduce body mass index in kids ages 6 to 11 with ...

But there's no guarantee of success here, nor will Novo Nordisk be getting anything tangible yet from its commitment to Korro. Therefore, it's a bit premature to take this latest development as a ...